Advanced Biomed Inc. (ADVB) Form 10-K — Oct 13, 2026
Advanced Biomed has fully exited biotechnology, selling Advanced Biomed HK for $23,000 and Advanced Biomed Taiwan for $490,000, and acquired Acellent Technologies in April 2026 to pivot to the FinTruth AI financial verification platform, its sole product. Fiscal 2026 revenue was only $127,637, and continuing operations lost $6,261,276; reported net income of $6,677,077 came almost entirely from a one-time $14,015,417 gain on disposing subsidiaries. Cash was just $385,535 at June 30, 2026, with $12.96 million of liquidity tied up in receivables from former subsidiaries whose collectability is uncertain after a $2,918,909 credit-loss provision.
Key figures
- Revenue
- 127637
- Net Income
- 6677077
- Total Debt
- 0
- Total Assets
- 0
- Cash Position
- 385535
- Shares Outstanding
- 1652133
- Gain on disposal
- 14015417
- Shareholder loan
- 600000
- Gross proceeds ipo
- approximately $6.56 million
- Loan interest rate
- 10% per annum
- Net current assets
- 12300000
- Reverse split ratio
- 1-for-20
- Net loss continuing ops
- 6261276
- Hk subsidiary sale price
- 23000
- Acellent acquisition value
- 1080000
- Non affiliate market value
- approximately $2.7 million as of December 31, 2025
- Private placement proceeds
- 248000
- Net income discontinued ops
- 12938353
- Taiwan subsidiary sale price
- 490000
- Provision expected credit losses
- 2918909
- Receivable due from former subsidiaries
- 12959826
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.